On November 21, 2022 Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch 3D genomics platform, reported that prominent medical oncologist, Dr. Steven Mamus, a regular user of EpiSwitch CiRT, will be speaking about OBD’s flagship test at the 2022 Liquid Biopsy Virtual Summit, 6 December 2022 (Press release, Oxford Biodynamics, NOV 21, 2022, View Source [SID1234624299]). OBD will also have a virtual booth with information and educational materials for the EpiSwitch CiRT.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This event, hosted by GenomeWeb and PMLS, will be an exceptional opportunity to present the unique benefit of EpiSwitch CiRT to accurately predict a cancer patient’s most likely response to ICI therapy with a simple blood sample through liquid biopsy. Building on his personal experience, Dr. Mamus will present the unique benefits of CiRT for oncologists in treatment planning and navigating complex decisions such as immune-related adverse events and pseudo-progression.
The event is regularly attended by renowned oncologists, pathologists, clinical lab managers, executives, pharmaceutical and biotech R&D professionals, and decision-makers at hospitals and healthcare systems.
Liquid biopsies, a key focus topic for this year’s event, offer several advantages over traditional tissue-based testing due to their non-invasive nature, avoiding a needle biopsy or surgical sampling, and capacity to allow continuous patient monitoring. OBD is the commercial pioneer and technological leader in isolating and analyzing 3D genomic biomarkers from a simple blood draw to guide treatment decisions, assess prognosis, and predict therapy response. In addition, the EpiSwitch platform allows researchers to comprehensively examine complex system-wide regulatory interactions between the host immune system and cancer to detect early cancer, predict its response to drugs, and even stratify patients to likely outcomes.
Please visit Precision Medicine Leaders’ Summit website, here, for more information. The virtual event is scheduled for December 6, 2022, from 10:00 am to 3:00 pm EST.
For more information about CiRT, please visit: www.myCiRT.com